Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

19.33 +0.10 (+0.52%)
Streaming Delayed Price Updated: 1:48 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
From BioMedWire
Via GlobeNewswire
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
From Denali Therapeutics Inc.
Via GlobeNewswire
Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More ↗
Via The Motley Fool
News headline image
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Board and Executive Leadership Updates
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate ↗
FDA extends review of Denali Therapeutics' tividenofusp alfa for Hunter syndrome to April 2026; analysts remain confident in its approval prospects. 
Via Benzinga
News headline image
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
What Happened To Denali Therapeutics Stock Wednesday? ↗
Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for the... 
Via Benzinga
News headline image
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback ↗
Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug. 
Via Benzinga
News headline image
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
From Denali Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.